Trust in Science LATAM

Trust in Science is a research funding initiative – launched by GSK in 2011 - designed to build a sustainable, long-term scientific research presence in Latin America. Through the programme, we are seeking partnerships with research groups to support projects and progress our shared goal of making new medicines available to the patients that need them.

Outdoor conversation

Trust in Science seeks to establish a strong collaboration with outstanding scientific groups in Latin America, in a creative way which includes a two-way exchange of knowledge, technologies, skills, training and information.

Since it launched in 2011, Trust in Science has provided a catalyst to validate and explore compelling ideas to treat priority diseases, including those that have a substantial impact on the health of Latin America.

Both in Brazil and Argentina we have partnered with Government Research Funding Agencies to increase the funding available for research projects.

In Brazil we are partnering with the Council of Science and Technology (CNPQ) as well as the Sao Paulo State Foundation for Research Support (FAPESP). In Argentina we are partnering with the Ministry of Science and Technology. Calls for project applications are made through the websites of our partners and are evaluated jointly.

For further information, please email us at trust.inscience@gsk.com.

Please select...

Design and synthesis of chemotherapeutic agents potentially active in Chagas' disease

Coordinator: Elizabeth Igne Ferreira, PhD

Faculty of Pharmaceutical Sciences, Department of Pharmacy, University of Sao Paolo

“The work we are developing with GSK in the Programme Trust in Science since November 2011 has been of the utmost importance for our group that involves researchers, graduate and post-doctors interested in neglected diseases, such as Chagas disease. We have had the opportunity of learning much about the pharmaceutical industry point of view, thanks to the permanent contact with researchers from GSK in Tres Cantos, Spain, and in London, through live meetings each two or three months. In those meetings we discuss our results and also some questions about our work, enriching our scientific knowledge towards finding promising drug candidates against Chagas disease. Trust in Science has been an excellent experience for our group and has decisively contributed to the development of our work. Initiatives like this must be emphasized and turned into permanent programmes for the benefit of our societies.”

Trust in Science Collaboration on Severe Asthma in Brazil

A case-control study of risk factors, endophenotypes and biomarkers

Coordinator - Professor Alvaro Cruz

“ProAR (Programme for Control of Asthma in Bahia) is a twofold academic initiative of Faculdade de Medicina da Bahia, Federal University of Bahia, started in 2002. It aimed at translating current knowledge into practice by building capacity of the public health system for asthma care, and investigating matters that are relevant to asthma prevention and control.

ProAR created reference centres for severe asthma in Salvador, the capital of the State of Bahia, Brasil. Over 4,000 patients with untreated severe asthma were enrolled in four reference centres and half of them have been followed up regularly, constituting an outpatient cohort of subjects with previously untreated severe asthma, for whom the best standard of care has been given for free.

In 2009 Professor Álvaro A. Cruz, the founder of ProAR and Scientist of the Brazilian Research Council (CNPq), received a grant from CNPq to develop a centre of excellence on asthma and a research programme to investigate risk factors, endophenotypes and biomarkers of severe asthma.This project has received the support of GSK Trust in Science, that offered funding and fostered collaboration with the U-Biopred European Consortium. Drs. Isro Gloger and David Myles (GSK) have accompanied closely the progresses and difficulties of the project implementation in monthly teleconferences and various face to face meetings, in which their wise advice has been much appreciated.

Across our business, we have broad interests in a number of important disease areas, so we are initially focusing on four research areas that are particularly strong in Latin America, and that are key priority areas for Government. These are:

  • Respiratory disease
  • Metabolic disease
  • Infectious diseases, especially neglected tropical diseases
  • Immunology and Inflammation

Within these disease areas, we are particularly interested in the following:

Respiratory diseases

  • Asthma
  • COPD
  • Acute lung injury
  • Cystic Fibrosis
  • Pulmonary Fibrosis

Metabolic diseases

  • Dyslipidemia
  • Obesity, diabetes Type I and Type II (includes diabetic secondary complications)
  • Metabolic Syndrome
  • Heart failure
  • Cachexia

Infectious and neglected diseases

  • Tropical Deceases (Malaria, Chagas, Leishmaniasis)
  • Rapid diagnostic systems for viral and bacterial infections
  • New approaches for treating viral (including HCV, HIV, RSV, HPV, HBV) and bacterial infections, including TB

Immunology and inflamation

  • Epigenetics Research
  • Reumathoid Arthritis
  • Inflammation processes in diesease
Back to top